Safer and more efficient fully human antibody discovery in as fast as 3 Months

Biointron and Cyagen have joined forces to create a breakthrough platform for discovering fully human antibodies. This collaboration combines Biointron's innovative AbDrop™ technology - a microdroplet-based platform for single B cell antibody discovery - with Cyagen's HUGO-Ab™ fully human antibody mice.

Fully human antibodies, entirely encoded by human genes, offer a significant advantage in antibody drug development. They trigger minimal immune response (immunogenicity) in patients, leading to improved safety and tolerance compared to traditional antibody therapies. This approach also focuses on identifying high-affinity and highly specific antibodies, ensuring they effectively target the desired molecules. Previously, researchers relied on humanized mice, genetically modified to produce human antibodies, for this purpose.

However, with the innovative combination of Biointron's AbDrop™ and Cyagen's HUGO-Ab™ mice enables more efficient fully human antibody discovery. Our High-throughput Fully Human Antibody Discovery Platform eliminates the need for complex modifications and simplifies the development process, reducing costs and accelerating the discovery of safer and more effective antibody drugs.

Our revolutionary platform paves the way for faster, more efficient, and cost-effective discovery of high-quality human antibodies, leading to better therapeutic options for patients. To learn more about this service, visit: https://www.biointron.com/antibody-discovery/high-throughput-fully-human-antibody-discovery-platform.html